The estimated Net Worth of Alan H Auerbach is at least 28.4 百万$ dollars as of 17 July 2024. Mr Auerbach owns over 21,920 units of Puma Biotechnology Inc stock worth over 17,658,788$ and over the last 12 years he sold PBYI stock worth over 5,060,264$. In addition, he makes 5,693,423$ as Founder、 Chairman、 Pres、 CEO & Sec. at Puma Biotechnology Inc.
Mr has made over 59 trades of the Puma Biotechnology Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 21,920 units of PBYI stock worth 81,104$ on 17 July 2024.
The largest trade he's ever made was selling 60,698 units of Puma Biotechnology Inc stock on 3 July 2023 worth over 200,910$. On average, Mr trades about 4,307 units every 33 days since 2012. As of 17 July 2024 he still owns at least 7,063,515 units of Puma Biotechnology Inc stock.
You can see the complete history of Mr Auerbach stock trades at the bottom of the page.
Alan H. Auerbach is the Founder, Chairman, Pres, CEO & Sec. at Puma Biotechnology Inc.
As the Founder、 Chairman、 Pres、 CEO & Sec. of Puma Biotechnology Inc, the total compensation of Mr Auerbach at Puma Biotechnology Inc is 5,693,423$. There are no executives at Puma Biotechnology Inc getting paid more.
Mr Auerbach is 51, he's been the Founder、 Chairman、 Pres、 CEO & Sec. of Puma Biotechnology Inc since . There are 12 older and 1 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
Alan's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES, CA, 90024.
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over 168,440,369$ worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth 48,866,148$ . The most active insiders traders include Capital Partners Gp, L.L.C....、Steven Lo、Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of 60,225$. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth 81,519$.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Puma Biotechnology Inc executives and other stock owners filed with the SEC include: